troglitazone has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute lymphoblastic leukemia (ALL) has previously been considered resistant to NK cell lysis and not tractable to this approach." | 1.39 | Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. ( Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jardine, L | 1 |
| Hambleton, S | 1 |
| Bigley, V | 1 |
| Pagan, S | 1 |
| Wang, XN | 1 |
| Collin, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies[NCT02169791] | Phase 2 | 29 participants (Actual) | Interventional | 2014-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To measure CD3 donor chimerism post-transplant (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|---|
| Haploidentical Transplant | 100 |
To measure CD33 donor chimerism at Day 30 (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|---|
| Haploidentical Transplant | 100 |
To measure days to onset of acute graft versus host disease (NCT02169791)
Timeframe: 100 days
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 28.5 |
To obtain time to neutrophil engraftment post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 16 |
To estimate the incidence of relapse/progression at one-year post-transplant. (NCT02169791)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Haploidentical Transplant | 10 |
To measure the time to platelet recovery post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 29 |
1 other study available for troglitazone and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Nat | 2013 |